COMP <GO>
ORGO vs UNH // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Organogenesis Holdings Inc. (Class A) (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ORGO 4
— UNH 6
■ METRIC PARITY
LAST: $0.77 (-6.20%) • MKT CAP: $105.4M
options-implied-move
—
LAST: $406.97 (-0.96%) • MKT CAP: $368.83B
options-implied-move
6.74%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORGO VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ORGO | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.10% | 11.47% | +5.63 | ORGO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -23.21% | 6.48% | -29.69 | UNH | /fcf-yield <GO> |
| Operating Margin | 7.90% | 4.82% | +3.08 | ORGO | /operating-margins <GO> |
| Net Profit Margin | 6.60% | 3.14% | +3.46 | ORGO | /net-margins <GO> |
| Revenue Growth (YoY) | 17.00% | 6.46% | +10.54 | ORGO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.09 | 3.12 | -1.03 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 15.6 | 59.2 | -43.59 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $105.4M | $368.83B | -$368.73B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ORGO REV | UNH REV | ORGO GROSS % | UNH GROSS % | ORGO FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $564.2M | $447.57B | — | 88.7% | -$24.5M | $16.07B |
| FY 2024 | $482.0M | $400.28B | 76.0% | 88.3% | $4.2M | $20.70B |
| FY 2023 | $433.1M | $371.62B | — | 89.6% | $30.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORGO // BETA —
UNH // BETA 0.33